MedTrace Logo

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

NCT00780494 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-01-14

Study results available
· View outcomes & findings →

Summary

To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers. We hope that by adding bevacizumab to standard chemotherapy for this patient population we will improve Progression Free Survival by 90% over historical controls.

Conditions

  • Stomach Cancer
  • Gastric (Stomach) Cancer
  • Neoplasm of Cardioesophageal Junction
  • Gastrointestinal Stromal Tumor (GIST)

Interventions

DRUG

bevacizumab

Intravenous 15 mg/kg

DRUG

carboplatin

AUC 6, Intravenously Day 1 every 21 days

DRUG

capecitabine

850mg/m2, Orally twice daily days 1-14 every 21 days.

Sponsors & Collaborators

Principal Investigators

  • Pamela Kunz, MD · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2017-12-31
Completion
2017-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00780494 on ClinicalTrials.gov